Overview of Novo Nordisk pharmaceutical products within diabetes, obesity, haemophilia, human growth hormone and hormone replacement therapy.

Jan 8, 2025 · Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence

At Novo Nordisk, you will have the opportunity to build a life-changing career in a global business environment. Join us and make a difference.

Dec 16, 2020 · Novo Nordisk Executive Management and other members of senior management provided a full review of our strategy, operations and financial targets. Download the presentations and watch the webcast

Medical events and congresses Here you can find an overview of all upcoming medical events and congresses where we are present, and search Novo Nordisk articles and congress materials.

Mar 24, 2023 · Novo Nordisk expects to file for regulatory approvals in the US and the EU in 2023. The global roll-out of the 25 mg and 50 mg doses is contingent on portfolio prioritisations and manufacturing capacity.

Aug 10, 2023 · Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes.

In compliance with regulations, we cannot provide detailed information about our prescription medicines on this website. In some cases, healthcare professionals and patients can visit local …

Introduction to type 2 diabetes and the current research we are conducting to find newer and better treatments for people living with the disease.

Nov 18, 2021 · Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders.